TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Figure 1. Nonnucleoside reverse transcriptase inhibitors (NNRTIs) prevent the conversion of viral RNA to viral DNA in the cytoplasm of human immunodeficiency virus (HIV)-1-infected CD4+ lymphocytes.

Use of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) is associated with an increased risk for primary ...

Dual Inhibitor: A compound designed to concurrently inhibit two distinct enzymatic activities, such as the polymerase and RNase H functions of reverse transcriptase or both RT and integrase.

Dr. Ali Ajaz - a doctor with a niche in ADHD who makes content about the condition on social media - has revealed the ...

Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of antiretroviral drugs that are used to treat HIV patients. NRTIs, developed in 1987, were the first drugs designed to treat HIV. They ...

"We need to continue learning more about the different versions of reverse transcriptase at work in the aging and especially the Alzheimer's disease brain," added Chun.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

a NNRTI = nonnucleoside reverse-transcriptase inhibitor, PI = protease inhibitor. b Unless otherwise stated, only adverse effects and changes in laboratory test values that occurred significantly ...